Abstract 1869P
Background
Despite the plethora of patient (pt) communication studies in the past decade, many of them include a diverse and heterogeneous pt and physician cohort. Thus, this single-centre prospective study aimed to measure gastrointestinal (GI) cancer pts' understanding of the information discussed during their first medical oncology visit and their satisfaction with the communication from subspecialized GI medical oncologists.
Methods
Between January and August 2021, chemotherapy-naïve pts in the gastrointestinal clinic at the Princess Margaret Cancer Centre (PMCC), Toronto, Canada, were consecutively approached within 24 hours of their initial consultation to complete a paper-based questionnaire about their understanding of their cancer (diagnosis, treatment plan/intent, prognosis) and satisfaction with the communication. GI medical oncologists concurrently completed a similar questionnaire. Pt and physician responses were compared to assess the degree of concordance. Uni/multivariable analyses were performed to identify pt/physician-based factors associated with concordance levels and pt satisfaction.
Results
A total of 184 matched pt-physician surveys were completed. The concordance rates for understanding of diagnosis, treatment plan, treatment intent, and prognosis were 92.9%, 59.2%, 66.8%, and 59.8%, respectively. Pts who reported treatment intent to be unclear at the time of the consultation were independently associated with lower satisfaction scores compared to those who reported their treatment intent to be curative (p=0.014). There was no statistical significance between patient satisfaction and whether prognosis was disclosed (p=0.08). Table: 1869P
N=184 | Fully concordant, n (%) | Partially concordant, n (%) | Fully discordant, n (%) | Missing, n (%) |
Diagnosis | 171 (92.9) | N/A | 10 (5.4) | 3 (1.6) |
Treatment Plan | 109 (59.2) | 75 (40.8) | 0 (0.0) | 0 (0.0) |
Treatment Intent | 123 (66.8) | N/A | 55 (29.9) | 6 (3.3) |
Prognosis | 110 (59.8) | N/A | 65 (35.3) | 9 (4.9) |
Conclusions
Pt understanding of treatment intent and prognosis after the first medical oncology consultation remain low. Further studies on the effectiveness of consultation aids in this setting are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Princess Margaret Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05